Changing clinical practice: Extending the benefits of adjuvant endocrine therapy in breast cancerGOSS, Paul E.Seminars in oncology. 2004, Vol 31, Num 6, pp 15-22, issn 0093-7754, 8 p., SUP12Article

Breaking the barriers: extending endocrine therapy beyond tamoxifenGOSS, Paul E.Seminars in oncology. 2004, Vol 31, Num 6, issn 0093-7754, 35 p., SUP12Serial Issue

Estrogen receptor pathway : Resistance to endocrine therapy and new therapeutic approachesMOY, Beverly; GOSS, Paul E.Clinical cancer research. 2006, Vol 12, Num 16, pp 4790-4793, issn 1078-0432, 4 p.Article

Tamoxifen resistant and refractory breast cancer: The value of aromatase inhibitorsGOSS, Paul E; STRASSER, Kathrin.Drugs (Basel). 2002, Vol 62, Num 6, pp 957-966, issn 0012-6667Article

Aromatase inhibitors in the treatment and prevention of breast cancerGOSS, Paul E; STRASSER, Kathrin.Journal of clinical oncology. 2001, Vol 19, Num 3, pp 881-894, issn 0732-183XArticle

Aromatase inhibitor withdrawal response in metastatic breast cancerCIGLER, Tessa; GOSS, Paul E.Journal of clinical oncology. 2006, Vol 24, Num 12, pp 1955-1956, issn 0732-183X, 2 p.Article

Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized ratsGOSS, Paul E; SHANGLE QI; HAIQING HU et al.Journal of steroid biochemistry and molecular biology. 2009, Vol 113, Num 3-5, pp 233-240, issn 0960-0760, 8 p.Article

Emerging role of aromatase inhibitors in the adjuvant settingGOSS, Paul E.American journal of clinical oncology. 2003, Vol 26, Num 4, pp S27-S33, issn 0277-3732, SUP1Article

Letrozole in the extended adjuvant setting : MA.17GOSS, Paul E.Breast cancer research and treatment. 2007, Vol 105, pp 45-53, issn 0167-6806, 9 p., SUP1Article

Aromatase inhibitors in early breast cancer therapySMITH, Ian E.Seminars in oncology. 2004, Vol 31, Num 6, pp 9-14, issn 0093-7754, 6 p., SUP12Article

Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapyHARVEY, Harold A.Seminars in oncology. 2004, Vol 31, Num 6, pp 23-30, issn 0093-7754, 8 p., SUP12Article

Aromatase inhibitors in advanced breast cancerMOURIDSEN, Henning T.Seminars in oncology. 2004, Vol 31, Num 6, pp 3-8, issn 0093-7754, 6 p., SUP12Article

Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 geneSUEN, Ting-Chung; GOSS, Paul E.Oncogene (Basingstoke). 2001, Vol 20, Num 4, pp 440-450, issn 0950-9232Article

Aromatase Inhibitors and Bone Health in Women With Breast CancerCHIEN, Amy Jo; GOSS, Paul E.Journal of clinical oncology. 2006, Vol 24, Num 33, pp 5305-5312, issn 0732-183X, 8 p.Article

Aromatase inhibitors in the management of early breast cancer: Optimizing the clinical benefitHENDERSON, I. Craig.Seminars in oncology. 2004, Vol 31, Num 6, pp 31-34, issn 0093-7754, 4 p., SUP12Article

Prevention of breast cancer using SERMs and aromatase inhibitorsSTRASSER-WEIPPL, Kathrin; GOSS, Paul E.Journal of mammary gland biology and neoplasia. 2003, Vol 8, Num 1, pp 5-18, issn 1083-3021, 14 p.Article

Characterization of a novel silencer element in the human aromatase gene PII promoterTIANRU JIN; XIAOYUN ZHANG; HUIQIN LI et al.Breast cancer research and treatment. 2000, Vol 62, Num 2, pp 151-159, issn 0167-6806Article

The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat modelGOSS, Paul E; SHANGLE QI; HAIQING HU et al.Breast cancer research and treatment. 2007, Vol 103, Num 3, pp 293-302, issn 0167-6806, 10 p.Article

Preventing relapse beyond 5 years : The MA.17 extended adjuvant trialGOSS, Paul E.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S8-S12, SUP7Article

Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort StudyLIEDKE, Pedro E. R; FINKELSTEIN, Dianne M; SZYMONIFKA, Jackie et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 1, pp 126-133, issn 1055-9965, 8 p.Article

Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver InjurySCHAID, Daniel J; SPRAGGS, Colin F; GOSS, Paul E et al.Journal of clinical oncology. 2014, Vol 32, Num 22, pp 2296-2303, issn 0732-183X, 8 p.Article

Decision making in adjuvant trials in breast cancer : the NCIC CTG MA.17 trial as an examplePATER, Joseph; DONGSHENG TU; SHEPHERD, Lois et al.Breast cancer research and treatment. 2008, Vol 108, Num 2, pp 265-269, issn 0167-6806, 5 p.Article

Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy : The UK perspectiveKARNON, Jonathan; DELEA, Thomas; JOHNSTON, Stephen R. D et al.PharmacoEconomics (Auckland). 2006, Vol 24, Num 3, pp 237-250, issn 1170-7690, 14 p.Article

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer : Updated findings from NCIC CTG MA.17GOSS, Paul E; INGLE, James N; LIVINGSTON, Robert B et al.Journal of the National Cancer Institute. 2005, Vol 97, Num 17, pp 1262-1271, issn 0027-8874, 10 p.Article

Adjuvant endocrine therapy options in hormone-dependent breast cancerSTRASSER-WEIPPL, Kathrin; GOSS, Paul E.European journal of cancer. Supplement (1990). 2005, Vol 3, Num 3, pp 247-254, issn 1359-6349, 8 p.Conference Paper